EverSource Wealth Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

EverSource Wealth Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.1K	Sell	873 -142	-14%	-$2.95K	﹤0.01%	2458
2026 Q1	$23.7K	Buy	1,015 +28	+3%	+$608	﹤0.01%	2393
2025 Q4	$20.7K	Buy	987 +374	+61%	+$6.53K	﹤0.01%	2360
2025 Q3	$9.43K	Buy	613 +599	+4,279%	+$7.84K	﹤0.01%	2851
2025 Q2	$131	Sell	14 -234	-94%	-$2.58K	﹤0.01%	4097
2025 Q1	$3.05K	Buy	248 +185	+294%	+$2.61K	﹤0.01%	2724
2024 Q4	$833	Buy	+63	New	+$1.08K	﹤0.01%	3027
2023 Q2	–	Sell	-64	Closed	-$1.35K	–	2597
2023 Q1	$1.35K	Buy	+64	New	+$1.59K	﹤0.01%	2046

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

EverSource Wealth Advisors's SNDX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Syndax Pharmaceuticals (SNDX) stake by 14% in Q2 2026, selling an estimated $2.95K and leaving 873 shares worth $19.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2458.

EverSource Wealth Advisors first reported a position in SNDX in Q1 2023 and has held it in 8 quarters since. The position peaked at $23.7K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

EverSource Wealth Advisors held 873 shares of Syndax Pharmaceuticals worth $19.1K as of Q2 2026.
EverSource Wealth Advisors sold 142 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.95K.
Syndax Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2458 holding.
EverSource Wealth Advisors first reported a position in Syndax Pharmaceuticals in Q1 2023 and has held it in 8 quarters since.
EverSource Wealth Advisors's Syndax Pharmaceuticals position peaked at $23.7K in Q1 2026.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.